Trial · NCT00295503

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

NCT00295503, Phase 2, Completed, University of Texas Southwestern Medical Center; results first posted 2017-01-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma. Trials, record NCT00295503. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00295503

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
NCT number: NCT00295503
Status: Completed
Phases: Phase 2
Enrollment: 53 participants, actual
Lead sponsor: University of Texas Southwestern Medical Center
Conditions: Mesothelioma
Interventions: bevacizumab, cisplatin, pemetrexed
First posted: 2006-02-23
Last updated: 2020-10-20
Results first posted: 2017-01-05

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival Rate at 6 Months	patients progression free at 6 months	This is the percentage of patients alive and progression-free at 6 months from initiation of treatment.
Secondary	Response Rate	from time of enrollment to time of best response or death from any cause, whichever came first up to 100 months	response was assessed by the RECIST criteria (version 1.0). Per those criteria, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Secondary	Overall Survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up 100 months	overall survival was measured from time of initiation of treatment to death from any cause

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Progression Free Survival Rate at 6 Months	patients progression free at 6 months	percentage of participants	NUMBER
SECONDARY	Response Rate	from time of enrollment to time of best response or death from any cause, whichever came first up to 100 months	percentage of participants	NUMBER
SECONDARY	Overall Survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up 100 months	months	MEDIAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression Free Survival Rate at 6 Months	Cisplatin, Pemetrexed, Bevacizumab	56		percentage of participants
Response Rate	Cisplatin, Pemetrexed, Bevacizumab	40		percentage of participants
Overall Survival	Cisplatin, Pemetrexed and Bevacizumab	14.8	95% Confidence Interval 10.0 to 17.0	months

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cisplatin, Pemetrexed and Bevacizumab	53
Overall Study	COMPLETED	Cisplatin, Pemetrexed and Bevacizumab	53
Overall Study	NOT COMPLETED	Cisplatin, Pemetrexed and Bevacizumab	0

Source ClinicalTrials.gov

Adverse events23

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Neutropenia	Blood and lymphatic system disorders	Experimental Arm	6	53	6
other	Thrombocytopenia	Blood and lymphatic system disorders	Experimental Arm	2	53	2
other	Anemia	Blood and lymphatic system disorders	Experimental Arm	1	53	1
other	Fatigue	General disorders	Experimental Arm	4	53	4
other	Constipation	Gastrointestinal disorders	Experimental Arm	2	53	2
other	Dehydration	General disorders	Experimental Arm	2	53	2
other	Neuropathy	Nervous system disorders	Experimental Arm	2	53	2
other	Allergic reaction	Immune system disorders	Experimental Arm	1	53	1
other	Anorexia	General disorders	Experimental Arm	1	53	1
other	Creatinine	Renal and urinary disorders	Experimental Arm	1	53	1

1 to 10 of 23Source ClinicalTrials.gov

See all 23 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Experimental Arm
Total, other adverse events	Experimental Arm	24	53
Total, serious adverse events	Experimental Arm	16	53

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00295503

GET https://conductscience.org/api/trials/v1/NCT00295503/events?page=2

API reference For AI assistants